Under the patronage of Márton Nagy, Minister of National Economy, the Hungarian Pharmaceutical Manufacturers Association (MAGYOSZ) held its annual conference, focusing on enhancing the competitiveness of the domestic and European pharmaceutical industry. In his speech, the minister emphasized that the pharmaceutical industry is a historical sector in Hungary and a crucial pillar of growth.

• mAbxience and Egis collaborate on the commercialization of two biosimilar candidates • The agreement covers eight Central and Eastern European countries with the potential for expansion into additional territories • mAbxience will serve as the marketing authorization holder, while Egis will manage commercialization in the designated regions

The red-black team of the Vas county town and one of the largest Hungarian pharmaceutical companies have extended their cooperation for another year. The team will continue to play under the name Egis Körmend in the championship.

Continuous modernisations and investment, launch of a new line of business, tree planting, exhibitions, and a short story contest. In 2023 Egis commemorated its 110th anniversary with a special series of events.

Egis Pharmaceuticals has announced that, backed by the Hungarian Competition Authority´s official certification, it has acquired one of Hungary´s well-known, locally applied dermatological product lines from Teva Pharmaceutical Industries Ltd. This move aims to strengthen Egis´s position in the Hungarian over-the-counter (OTC) market.

Throughout the year our company has celebrated the 110th anniversary of its foundation. Not only several initiatives have been launched to commemorate this notable event, but the jubilee year also presented a great opportunity to look back on the past eleven decades of our company.

Egis Polska received Friendly Workplace Award and Great Place to Work title

The selection process for the position of Egis Group’s Commercial Director has been closed. As a result, dr Csaba Pácz remains head of the Commercial Directorate.

On the Egis Health and Prevention Days in Kőbánya participants were provided information on their health status

We have commemorated World Cancer Day.

As Diamond Sponsor of the comprehensive nationwide health tests program (MÁESZ), our company considers the protection of health to be top priority.

Egis Pharmaceutical PLC is committed to support the safety of medical staff in the current pandemic situation.

he project identified as 2020-1.1.2-PIACI-KFI-2020-00039, conducted by Egis Pharmaceuticals PLC and its consortium partner, the HUN-REN Research Centre for Natural Sciences (TTK), finished on December 31, 2024.

Two of Egis’ fixed-dose combination drugs have won the Innovation Grand Prize. The awarded Egis medicines feature significant innovations as they reduce the risk of cardiovascular events related to atherosclerosis due to the combined lipid-lowering therapy. In respect of these two products the company obtained three patents related to active ingredient development and two patents related to formulation development that are all relevant to large-scale manufacturing technologies. The recognition was not without a history, as this is the tenth time an Egis medicine has received an Innovation Prize or Grand Prize.

Egis Pharmaceuticals PLC, celebrating the 110th anniversary of its foundation this year, is expanding its usual activities with new elements thanks to investments exceeding a total value of more than HUF 100 billion in Hungary over the past decade.  Egis, one of the leading generic pharmaceutical companies in Eastern and Central Europe, now offers drug substance contract development and contract manufacturing services under the name of Egis Pharma Services to both existing and new pharmaceutical partners.

Two technology-intensive developments, carried out with state subsidies, were completed at Egis Pharmaceuticals PLC’s Körmend site (Hungary). The investments were inaugurated by Péter Szijjártó, Minister of Foreign Affairs and Trade, and by the company’s CEO, Dr. István Hodász on 15 October.  In addition to a new packaging plant, Egis has also established a plant with special knowledge and technology requirements, typically suitable to manufacture oncology products.  Thus, Egis is now able to implement all value-creating processes within the field of oncology, from development to active ingredient and finished product manufacturing.

One of the streets of the town has become greener.

We are proud to have contributed to the recognition of the most innovative young people.

Students studying for their advanced level secondary school-leaving exam can benefit from the new feature of the Colourful Chemistry platform. The downloadable collection of exercises can help students in the second part of the advanced exam, when they have to perform or explain some experiments.

We are inviting secondary school students interested in the practical application of chemistry to take part in our special competition, organized together with Researchers’ Night. The first round will be held online then the groups of three will compete at the Egis Science and Technology Centre in September.

The Hungarian Innovation Association, in collaboration with the Hungarian Innovation Foundation, announced the contest for the 2024 Innovation Grand Prize at the Egis Science and Technology Center. The significance of the award is highlighted by the fact that innovative companies can apply for the 33rd time for the competition, which will conclude with a ceremonial award ceremony next spring.

In Hungary, industries closely related to chemistry – the chemical industry, pharmaceutical industry, and environmental industry – have significant national economic weight, yet these sectors face above-average labor shortages.

On the Night of Museums, our programme was quite a popular one: we had more than 120 visitors on this special night. The places were snapped up so quickly that after a few days, we had to close the registration.

On the Night of Museums, we welcomed visitors in three groups in the Egis Science and Technology Centre. Many people expressed their interest in the everyday life of a pharmaceutical company and places were snapped up so quickly that after a few days we had to close the registration.